Earnings call Transcript
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Viyash Scientific reported its strongest quarter in company history with Q4 FY26 EBITDA of INR200 crores. For full year FY26, revenue reached INR3,420 crores (up 14% YoY) with EBITDA at INR702 crores (up 60%) and PAT at INR225 crores (up 14x from INR16 crores). Gross margins expanded by 321 bps to 54.3%. The company highlighted successful integration post-merger, with synergies tracking at INR50-60 crores annualized and expected to reach INR125-150 crores in 12-18 months. Animal health API broke a 5-year plateau, growing from INR350 crores to INR400 crores. CDMO lifecycle management business (currently ~INR200 crores) is expected to grow 40% in FY27. Management targets 15% revenue growth and mentioned an upcoming investor meeting to discuss detailed multi-year strategic plan. The company also announced credit rating upgrade to AA-.
Strong operational performance with margin expansion reflects successful integration execution. The company is investing heavily in R&D and companion animal segment (pet health) as a strategic growth driver. With balance sheet deleveraged and cash generation strong, the stock appears well-positioned for sustained growth.